1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The inflammatory bowel disease (IBD) treatment market is rapidly advancing, driven by innovation in therapeutics, shifting patient expectations, and changes in market access. Senior leaders increasingly prioritize informed strategies as evolving treatment paradigms, regulatory pressures, and global economic changes reshape the competitive landscape.
Market Snapshot: Inflammatory Bowel Disease Treatment Market
The inflammatory bowel disease treatment market grew from USD 20.01 billion in 2024 to USD 20.95 billion in 2025. It is expected to continue growing at a CAGR of 4.83%, reaching USD 26.56 billion by 2030. This growth is underpinned by technological advances in precision medicine, wider adoption of biologics, and evolving reimbursement frameworks. As global IBD prevalence rises and provider networks expand digital capabilities, the market’s landscape continues to shift toward more specialized, patient-centric care models.
Scope & Segmentation
- Treatment Types: Advanced therapies (gene therapy, microbiome modulators, stem cell therapy), biologics (integrin receptor antagonists, interleukin inhibitors, TNF inhibitors), small molecule drugs (aminosalicylates, corticosteroids, immunosuppressants), and surgical procedures (ostomy, resection, strictureplasty).
- Routes of Administration: Injectable (intravenous, subcutaneous), oral, and rectal formulations.
- Formulation Types: Liquid formulations (oral solutions, suspensions), parenteral preparations, and solid dosage forms (chewable tablets, extended release tablets).
- Applications: Targeting Crohn’s disease, ulcerative colitis, and indeterminate colitis.
- End-Users: Clinics, hospitals, and home care settings.
- Distribution Channels: Hospital pharmacies, retail pharmacies, and online platforms.
- Patient Types: Adult, geriatric, and pediatric populations.
- Key Regions: Americas (notably United States, Canada, Brazil); Europe, Middle East & Africa (including United Kingdom, Germany, France, Saudi Arabia, South Africa); and Asia-Pacific (with China, India, Japan, Australia, South Korea, and Southeast Asian markets).
Key Takeaways
- The adoption of advanced biologic and gene therapies is accelerating, supported by R&D investments and a shift toward personalized treatment in high-income regions.
- Small molecule drugs and conventional immunosuppressants persist as essential options for induction, maintenance therapy, and as cost-effective choices in payer-sensitive markets.
- Emerging digital solutions—including telemedicine platforms and remote monitoring—enable better treatment adherence and earlier interventions, aligning with healthcare digitization trends.
- Patient stratification by disease subtype, administration route, and formulation increases competitive differentiation as stakeholders seek to address unmet needs across age groups and disease presentations.
- Collaboration between pharmaceutical companies and biotech innovators, especially for advanced therapies and manufacturing partnerships, drives portfolio diversification and operational resilience.
- Shifting payer and regulatory expectations demand robust evidence of value—clinical and economic—impacting price negotiations and market uptake strategies.
Tariff Impact
Recent US tariff policies have increased costs for imported pharmaceutical ingredients and specialized reagents, prompting manufacturers to reconsider global supply chain models. These cost shifts affect negotiations with payers, emphasize value-based agreements, and create disparities in market access and affordability by region. Some distributors absorb increased costs to preserve market share, while others adjust pricing structures for providers and health systems. As a result, market participants adapt their sourcing, partnership, and rebate strategies to mitigate disruptions and optimize market presence.
Methodology & Data Sources
This analysis integrates primary interviews with key opinion leaders and senior industry executives, alongside mining of clinical registries, regulatory filings, and proprietary databases. Structured segmentation, regional analyses, and strict quality assurances ensure reliable, actionable insights. Forecasting was intentionally not applied to prevent speculative bias.
Why This Report Matters
- Delivers a comprehensive overview of IBD therapeutic innovation, commercialization strategies, and regulatory shifts that enable confident investment and product planning decisions.
- Equips executives with actionable, segmented insights into patient needs, technology adoption, and competitive positioning across multiple regions and care settings.
- Supports proactive responses to macroeconomic challenges, including tariff impacts and changing payer incentives, to strengthen resilience and capture emerging market opportunities.
Conclusion
Strategic adaptation to evolving technologies, shifting regulatory demands, and patient-centric care models will define future success in IBD treatment. Decision-makers who act on robust, evidence-based insights are best positioned to capture value and enhance outcomes in this expanding therapeutic area.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. An Overview of Inflammatory Bowel Disease Treatment Market Evolution and Its Impact Across Industries
3.2. A Detailed Examination of Consumer Preferences Competitive Dynamics and Regulatory Variability in the IBD Treatment Market
3.3. An In-Depth Analysis of Market Stage Intellectual Property Landscape and Strategic Commercialization Approaches in IBD Treatment
3.4. Future Market Outlook Trends and Technological Innovations Shaping the Inflammatory Bowel Disease Treatment Landscape
3.2. A Detailed Examination of Consumer Preferences Competitive Dynamics and Regulatory Variability in the IBD Treatment Market
3.3. An In-Depth Analysis of Market Stage Intellectual Property Landscape and Strategic Commercialization Approaches in IBD Treatment
3.4. Future Market Outlook Trends and Technological Innovations Shaping the Inflammatory Bowel Disease Treatment Landscape
4. Market Overview
4.1. Introduction
4.1.1. Comprehensive Market Definition and Economic Significance with Growth Drivers and Innovation Needs in Inflammatory Bowel Disease Treatment
4.1.2. In-Depth Geographic Evaluation of Regional Market Dynamics Trade and Cultural Influences in Inflammatory Bowel Disease Treatment
4.1.3. Summary of Recent Innovations Regulatory Changes and Strategic Industry Developments Impacting Inflammatory Bowel Disease Treatment
4.2. Market Sizing & Forecasting
4.1.1. Comprehensive Market Definition and Economic Significance with Growth Drivers and Innovation Needs in Inflammatory Bowel Disease Treatment
4.1.2. In-Depth Geographic Evaluation of Regional Market Dynamics Trade and Cultural Influences in Inflammatory Bowel Disease Treatment
4.1.3. Summary of Recent Innovations Regulatory Changes and Strategic Industry Developments Impacting Inflammatory Bowel Disease Treatment
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growing emphasis on minimally invasive therapies for better patient compliance in IBD
5.1.1. Clear definition and contextual background of the growing emphasis on minimally invasive therapies in IBD treatment
5.1.2. Comprehensive analysis of how minimally invasive therapies transform the IBD treatment market landscape and create new business opportunities
5.1.3. Future outlook on the trajectory and implications of minimally invasive therapies in IBD treatment with strategic recommendations
5.2. Rising adoption of personalized medicine approaches in managing inflammatory bowel disease
5.2.1. Comprehensive definition and contextual background of personalized medicine in inflammatory bowel disease management
5.2.2. How personalized medicine adoption transforms the inflammatory bowel disease market landscape and creates new business opportunities
5.2.3. Future outlook on personalized medicine in IBD treatment including opportunities, challenges, and strategic recommendations
5.3. Increased focus on gut microbiome modulation as a novel IBD therapeutic strategy
5.3.1. Trend Definition and Context Behind the Increasing Focus on Gut Microbiome Modulation for IBD Therapeutics
5.3.2. How the Increased Focus on Gut Microbiome Modulation Is Transforming Market Dynamics and Creating Opportunities in IBD Treatment
5.3.3. Future Outlook on the Growing Role of Gut Microbiome Modulation and Its Long-Term Implications for IBD Treatment Market
5.4. Expanding pipeline of small molecule drugs offering alternative treatments for IBD
5.4.1. Comprehensive definition and contextual background of the expanding small molecule drug pipeline trend in IBD treatment
5.4.2. Analysis of how the growth in small molecule drugs is reshaping the IBD market landscape with new business opportunities
5.4.3. Future outlook, long-term implications, and strategic considerations for stakeholders amid the rise of small molecule therapies in IBD treatment
5.5. Advancements in targeted drug delivery systems improving efficacy in IBD therapies
5.5.1. Comprehensive definition and contextual background of advancements in targeted drug delivery systems enhancing IBD treatment efficacy
5.5.2. Analysis of market transformation and newly created opportunities through targeted drug delivery systems in IBD therapy
5.5.3. Future projections and strategic considerations for advancements in IBD targeted drug delivery systems
5.6. Integration of digital health technologies for remote monitoring of IBD patients
5.6.1. Comprehensive explanation of integration of digital health technologies for remote monitoring of IBD patients and its driving factors
5.6.2. Analysis of how integration of digital health technologies is transforming IBD treatment markets and unlocking business opportunities
5.6.3. Future trajectory and implications of digital health integration for IBD remote monitoring with strategic recommendations
5.7. Shift towards combination therapies to enhance treatment outcomes in inflammatory bowel disease
5.7.1. Detailed explanation and background of combination therapy trend in IBD treatment including driving factors
5.7.2. Comprehensive market impact analysis of combination therapy trend revealing opportunities and innovation
5.7.3. Future outlook and implications of combination therapy trend considering challenges and opportunities
5.8. Surge in awareness and early diagnosis driving demand for innovative IBD treatments
5.8.1. Comprehensive overview and contextual background of the surge in awareness and early diagnosis trend impacting the IBD treatment market
5.8.2. In-depth analysis of how increased awareness and early diagnosis are reshaping market dynamics and fostering innovation in IBD treatment
5.8.3. Future trajectory, long-term implications, and strategic recommendations for stakeholders amidst the rise of awareness and early diagnosis in IBD treatment
5.9. Impact of regulatory approvals accelerating launch of next-generation IBD therapies
5.9.1. Comprehensive definition and contextual background of accelerated regulatory approvals in next-generation IBD therapies
5.9.2. In-depth analysis of market transformation and business opportunities driven by faster regulatory approvals for IBD therapeutics
5.9.3. Future outlook on the implications and strategic considerations related to rapid regulatory approvals in the IBD market
5.10. Emergence of biologics and biosimilars transforming IBD treatment options globally
5.10.1. Clearly defining the emergence of biologics and biosimilars in IBD treatment and its market context
5.10.2. Analyzing the market impact of biologics and biosimilars transforming IBD treatment worldwide
5.10.3. Discussing the future outlook and implications of biologics and biosimilars in IBD treatment globally
5.1.1. Clear definition and contextual background of the growing emphasis on minimally invasive therapies in IBD treatment
5.1.2. Comprehensive analysis of how minimally invasive therapies transform the IBD treatment market landscape and create new business opportunities
5.1.3. Future outlook on the trajectory and implications of minimally invasive therapies in IBD treatment with strategic recommendations
5.2. Rising adoption of personalized medicine approaches in managing inflammatory bowel disease
5.2.1. Comprehensive definition and contextual background of personalized medicine in inflammatory bowel disease management
5.2.2. How personalized medicine adoption transforms the inflammatory bowel disease market landscape and creates new business opportunities
5.2.3. Future outlook on personalized medicine in IBD treatment including opportunities, challenges, and strategic recommendations
5.3. Increased focus on gut microbiome modulation as a novel IBD therapeutic strategy
5.3.1. Trend Definition and Context Behind the Increasing Focus on Gut Microbiome Modulation for IBD Therapeutics
5.3.2. How the Increased Focus on Gut Microbiome Modulation Is Transforming Market Dynamics and Creating Opportunities in IBD Treatment
5.3.3. Future Outlook on the Growing Role of Gut Microbiome Modulation and Its Long-Term Implications for IBD Treatment Market
5.4. Expanding pipeline of small molecule drugs offering alternative treatments for IBD
5.4.1. Comprehensive definition and contextual background of the expanding small molecule drug pipeline trend in IBD treatment
5.4.2. Analysis of how the growth in small molecule drugs is reshaping the IBD market landscape with new business opportunities
5.4.3. Future outlook, long-term implications, and strategic considerations for stakeholders amid the rise of small molecule therapies in IBD treatment
5.5. Advancements in targeted drug delivery systems improving efficacy in IBD therapies
5.5.1. Comprehensive definition and contextual background of advancements in targeted drug delivery systems enhancing IBD treatment efficacy
5.5.2. Analysis of market transformation and newly created opportunities through targeted drug delivery systems in IBD therapy
5.5.3. Future projections and strategic considerations for advancements in IBD targeted drug delivery systems
5.6. Integration of digital health technologies for remote monitoring of IBD patients
5.6.1. Comprehensive explanation of integration of digital health technologies for remote monitoring of IBD patients and its driving factors
5.6.2. Analysis of how integration of digital health technologies is transforming IBD treatment markets and unlocking business opportunities
5.6.3. Future trajectory and implications of digital health integration for IBD remote monitoring with strategic recommendations
5.7. Shift towards combination therapies to enhance treatment outcomes in inflammatory bowel disease
5.7.1. Detailed explanation and background of combination therapy trend in IBD treatment including driving factors
5.7.2. Comprehensive market impact analysis of combination therapy trend revealing opportunities and innovation
5.7.3. Future outlook and implications of combination therapy trend considering challenges and opportunities
5.8. Surge in awareness and early diagnosis driving demand for innovative IBD treatments
5.8.1. Comprehensive overview and contextual background of the surge in awareness and early diagnosis trend impacting the IBD treatment market
5.8.2. In-depth analysis of how increased awareness and early diagnosis are reshaping market dynamics and fostering innovation in IBD treatment
5.8.3. Future trajectory, long-term implications, and strategic recommendations for stakeholders amidst the rise of awareness and early diagnosis in IBD treatment
5.9. Impact of regulatory approvals accelerating launch of next-generation IBD therapies
5.9.1. Comprehensive definition and contextual background of accelerated regulatory approvals in next-generation IBD therapies
5.9.2. In-depth analysis of market transformation and business opportunities driven by faster regulatory approvals for IBD therapeutics
5.9.3. Future outlook on the implications and strategic considerations related to rapid regulatory approvals in the IBD market
5.10. Emergence of biologics and biosimilars transforming IBD treatment options globally
5.10.1. Clearly defining the emergence of biologics and biosimilars in IBD treatment and its market context
5.10.2. Analyzing the market impact of biologics and biosimilars transforming IBD treatment worldwide
5.10.3. Discussing the future outlook and implications of biologics and biosimilars in IBD treatment globally
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.1.1. Analyzing the Threat of New Entrants Considering Barriers Such as Capital, Regulation, and Brand Loyalty in the IBD Treatment Market
6.1.2. Evaluating the Impact of Alternative Therapies and Technological Advances on the Threat of Substitutes in IBD Treatment
6.1.3. Assessing Supplier Influence Through Input Scarcity and Supply Chain Stability in the IBD Treatment Market
6.1.4. Understanding Buyer Influence Through Price Sensitivity and Alternative Options in the IBD Treatment Market
6.1.5. Examining Competitive Rivalry Through Innovation, Market Share, and Pricing Strategies in the IBD Treatment Market
6.2. PESTLE Analysis
6.2.1. Political factors crucially influencing healthcare policies and regulatory frameworks in the IBD treatment market
6.2.2. Economic dynamics affecting healthcare expenditure, patient affordability, and pharmaceutical operations in the IBD treatment market
6.2.3. Social trends driving patient awareness, demographic shifts, and demand for patient-centric IBD treatments
6.2.4. Technological innovations in biologics, personalized medicine, and digital health transforming IBD treatment
6.2.5. Legal frameworks governing drug approval, intellectual property, and data privacy in the IBD treatment market
6.2.6. Environmental pressures and sustainability initiatives influencing production and supply reliability in the IBD treatment market
6.1.1. Analyzing the Threat of New Entrants Considering Barriers Such as Capital, Regulation, and Brand Loyalty in the IBD Treatment Market
6.1.2. Evaluating the Impact of Alternative Therapies and Technological Advances on the Threat of Substitutes in IBD Treatment
6.1.3. Assessing Supplier Influence Through Input Scarcity and Supply Chain Stability in the IBD Treatment Market
6.1.4. Understanding Buyer Influence Through Price Sensitivity and Alternative Options in the IBD Treatment Market
6.1.5. Examining Competitive Rivalry Through Innovation, Market Share, and Pricing Strategies in the IBD Treatment Market
6.2. PESTLE Analysis
6.2.1. Political factors crucially influencing healthcare policies and regulatory frameworks in the IBD treatment market
6.2.2. Economic dynamics affecting healthcare expenditure, patient affordability, and pharmaceutical operations in the IBD treatment market
6.2.3. Social trends driving patient awareness, demographic shifts, and demand for patient-centric IBD treatments
6.2.4. Technological innovations in biologics, personalized medicine, and digital health transforming IBD treatment
6.2.5. Legal frameworks governing drug approval, intellectual property, and data privacy in the IBD treatment market
6.2.6. Environmental pressures and sustainability initiatives influencing production and supply reliability in the IBD treatment market
7. Cumulative Impact of United States Tariffs 2025
7.1. Historical background and economic rationale behind United States tariff policies from 2018 to 2025
7.2. Analysis of direct inflationary effects attributed to recent United States tariff implementations
7.3. Examination of reciprocal tariffs and trade wars involving the United States and major global regions
7.4. Evaluation of economic and political impacts of United States tariffs on major trading partners
7.5. Identification of long-term structural changes in the U S economy due to tariff policies and consumer impact
7.6. Suggested policy responses and strategies to mitigate negative impacts of tariffs on the United States economy and trading partners
7.2. Analysis of direct inflationary effects attributed to recent United States tariff implementations
7.3. Examination of reciprocal tariffs and trade wars involving the United States and major global regions
7.4. Evaluation of economic and political impacts of United States tariffs on major trading partners
7.5. Identification of long-term structural changes in the U S economy due to tariff policies and consumer impact
7.6. Suggested policy responses and strategies to mitigate negative impacts of tariffs on the United States economy and trading partners
8. Inflammatory Bowel Disease Treatment Market, by Treatment Type
8.1. Introduction
8.2. Advanced Therapies
8.2.1. Gene Therapy
8.2.2. Microbiome Modulators
8.2.3. Stem Cell Therapy
8.3. Biologics
8.3.1. Integrin Receptor Antagonists
8.3.2. Interleukin Inhibitors
8.3.3. TNF Inhibitors
8.4. Small Molecule Drugs
8.4.1. Aminosalicylates
8.4.2. Corticosteroids
8.4.3. Immunosuppressants
8.5. Surgical Procedures
8.5.1. Ostomy
8.5.2. Resection
8.5.3. Strictureplasty
8.2. Advanced Therapies
8.2.1. Gene Therapy
8.2.2. Microbiome Modulators
8.2.3. Stem Cell Therapy
8.3. Biologics
8.3.1. Integrin Receptor Antagonists
8.3.2. Interleukin Inhibitors
8.3.3. TNF Inhibitors
8.4. Small Molecule Drugs
8.4.1. Aminosalicylates
8.4.2. Corticosteroids
8.4.3. Immunosuppressants
8.5. Surgical Procedures
8.5.1. Ostomy
8.5.2. Resection
8.5.3. Strictureplasty
9. Inflammatory Bowel Disease Treatment Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Intravenous
9.2.2. Subcutaneous
9.3. Oral
9.4. Rectal
9.2. Injectable
9.2.1. Intravenous
9.2.2. Subcutaneous
9.3. Oral
9.4. Rectal
10. Inflammatory Bowel Disease Treatment Market, by Formulation Type
10.1. Introduction
10.2. Liquid Formulations
10.2.1. Oral Solutions
10.2.2. Suspensions
10.3. Parenteral Preparations
10.4. Solid Dosage Forms
10.4.1. Chewable Tablets
10.4.2. Extended Release Tablets
10.2. Liquid Formulations
10.2.1. Oral Solutions
10.2.2. Suspensions
10.3. Parenteral Preparations
10.4. Solid Dosage Forms
10.4.1. Chewable Tablets
10.4.2. Extended Release Tablets
11. Inflammatory Bowel Disease Treatment Market, by Application
11.1. Introduction
11.2. Crohns Disease
11.3. Indeterminate Colitis
11.4. Ulcerative Colitis
11.2. Crohns Disease
11.3. Indeterminate Colitis
11.4. Ulcerative Colitis
12. Inflammatory Bowel Disease Treatment Market, by End-User
12.1. Introduction
12.2. Clinics
12.3. Home Care Settings
12.4. Hospitals
12.2. Clinics
12.3. Home Care Settings
12.4. Hospitals
13. Inflammatory Bowel Disease Treatment Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Inflammatory Bowel Disease Treatment Market, by Patient Type
14.1. Introduction
14.2. Adult Population
14.3. Geriatric Population
14.4. Pediatric Population
14.2. Adult Population
14.3. Geriatric Population
14.4. Pediatric Population
15. Americas Inflammatory Bowel Disease Treatment Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Inflammatory Bowel Disease Treatment Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Inflammatory Bowel Disease Treatment Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.1.1. A Comprehensive Overview of Abbott Laboratories' Strategic Position and Market Presence in IBD Treatment
18.3.1.2. In-Depth Analysis of Abbott Laboratories' Flagship Products and Services Catering to IBD Treatment Needs
18.3.1.3. Strategic Risk and Vulnerability Assessment with Actionable Growth Enhancement Strategies for Abbott Laboratories in IBD Treatment
18.3.2. AbbVie Inc.
18.3.2.1. In-depth Analysis of AbbVie's Flagship Products and Services Delivering Solutions in IBD Therapy
18.3.2.2. Comprehensive Risk and Vulnerability Assessment with Strategic Growth Recommendations for AbbVie in IBD Treatment
18.3.3. Abivax
18.3.3.1. In-depth analysis of Abivax's flagship IBD treatment products highlighting unique clinical benefits and market differentiation
18.3.3.2. Comprehensive risk and vulnerability assessment with actionable strategies for growth and market resilience
18.3.4. Amgen Inc.
18.3.4.1. Comprehensive analysis of flagship products and services in the inflammatory bowel disease segment catering to patient and healthcare provider needs
18.3.4.2. Strategic risk assessment and vulnerability management to sustain growth and innovation in the inflammatory bowel disease treatment market
18.3.5. Bristol-Myers Squibb Company
18.3.5.1. Detailed Analysis of Bristol-Myers Squibb's Flagship Products and Their Market Relevance with Differentiators
18.3.5.2. Comprehensive Risk and Vulnerability Assessment with Strategic Recommendations for Bristol-Myers Squibb’s Future Growth in IBD Treatment Market
18.3.6. Cipla Limited
18.3.6.1. Comprehensive overview of Cipla Limited’s current role strategic positioning and core strengths in the pharmaceutical market including established presence and geographic influence
18.3.6.2. In-depth analysis of Cipla Limited’s flagship products and services for Inflammatory Bowel Disease treatment outlining key features and market alignment
18.3.6.3. Strategic risk and vulnerability assessment for Cipla Limited with actionable strategies to improve product portfolio and market positioning in evolving industry landscape
18.3.7. Eli Lilly and Company
18.3.7.1. In-depth examination of Eli Lilly’s flagship biologic therapies and their alignment with evolving patient needs in inflammatory bowel disease treatment
18.3.7.2. Comprehensive risk and vulnerability assessment with strategic recommendations for enhancing Eli Lilly’s market positioning in inflammatory bowel disease
18.3.8. Entera Bio Ltd.
18.3.8.1. Detailed analysis of Entera Bio Ltd company’s flagship products and services that define its market edge
18.3.8.2. Comprehensive risk and vulnerability assessment with actionable strategies for Entera Bio Ltd to strengthen its market position
18.3.9. FutureGen Biopharmaceutical (Beijing) Co., Ltd.
18.3.9.1. Comprehensive Analysis of Flagship Products and Services Highlighting Market Differentiators and Customer Alignment
18.3.9.2. Detailed Risk and Vulnerability Assessment With Strategic Recommendations to Strengthen Market Position and Innovation Pipeline
18.3.10. GlaxoSmithKline PLC
18.3.10.1. Detailed overview and analysis of flagship products and services focusing on inflammatory bowel disease treatment
18.3.10.2. Comprehensive risk and vulnerability assessment with actionable strategies for product and market enhancement over the next years
18.3.11. Ironwood Pharmaceuticals, Inc.
18.3.11.1. In-depth Analysis of Ironwood Pharmaceuticals’ Flagship Products and Their Market Alignment with IBD Treatment Needs
18.3.11.2. Comprehensive Risk and Vulnerability Assessment of Ironwood Pharmaceuticals with Strategic Growth Enhancement Approaches
18.3.12. Johnson & Johnson Services, Inc.
18.3.12.1. Flagship Products and Services Highlighting Their Unique Features and Market Impact
18.3.12.2. In-Depth Risk Assessment and Strategies to Strengthen Product Portfolio and Market Position Over Time
18.3.13. Merck & Co., Inc.
18.3.13.1. In-depth identification and analysis of the company’s flagship products or services that directly cater to the target market
18.3.13.2. Comprehensive assessment of risks, vulnerabilities, and strategic opportunities to enhance market position and product portfolio over the coming years
18.3.14. Morphic Therapeutic, Inc.
18.3.14.1. In-depth Analysis of Morphic Therapeutic’s Flagship Products and Their Market Alignment
18.3.14.2. Comprehensive Risk and Vulnerability Assessment with Strategic Growth Recommendations for Morphic Therapeutic
18.3.15. Nestlé S.A.
18.3.15.1. Detailed Analysis of Nestlé's Flagship Products and Services That Cater to Inflammatory Bowel Disease Treatment Market
18.3.15.2. Comprehensive Risk and Vulnerability Assessment with Strategies for Enhanced Growth in the Inflammatory Bowel Disease Treatment Market
18.3.16. OPKO Health, Inc.
18.3.16.1. In-depth Analysis of OPKO Healths Flagship Products and Services Driving Market Relevance
18.3.16.2. Comprehensive Risk and Vulnerability Assessment with Strategic Recommendations for Sustained Growth and Market Expansion
18.3.17. Pfizer Inc.
18.3.17.1. Detailed analysis of Pfizer's leading products directly addressing the inflammatory bowel disease market
18.3.17.2. Comprehensive evaluation of potential risks, vulnerabilities, and strategic growth opportunities for Pfizer in the inflammatory bowel disease treatment market
18.3.18. Sanofi SA
18.3.18.1. Detailed analysis of Sanofi's flagship products and services addressing inflammatory bowel disease treatment needs and market differentiation
18.3.18.2. Comprehensive assessment of risks and vulnerabilities with strategic recommendations for innovation and market expansion in Sanofi's inflammatory bowel disease portfolio
18.3.19. Sun Pharma Limited
18.3.19.1. Identification and In-depth Analysis of Sun Pharma's Flagship Products and Core Services Addressing IBD Treatment Needs
18.3.19.2. Comprehensive Risk and Vulnerability Assessment Identifying Strategic Growth Opportunities for Sun Pharma in IBD Treatment Market
18.3.20. Takeda Pharmaceutical Company Limited
18.3.20.1. In-depth Review of Takeda Pharmaceutical Company Limited’s Flagship Products and Services Targeting Inflammatory Bowel Disease Patients
18.3.20.2. Comprehensive Risk and Vulnerability Analysis with Strategic Recommendations for Takeda in the Inflammatory Bowel Disease Market
18.3.21. Teva Pharmaceutical Industries Ltd.
18.3.21.1. In-depth Analysis of Teva Pharmaceutical's Flagship Products Addressing Inflammatory Bowel Disease Treatment Needs
18.3.21.2. Comprehensive Risk And Vulnerability Assessment Highlighting Strategic Growth Opportunities For Teva Pharmaceutical Industries Ltd
18.3.22. TScan Therapeutics, Inc.
18.3.22.1. In-depth Analysis of TScan Therapeutics’ Flagship Products and Services Targeted at Inflammatory Bowel Disease Treatment
18.3.22.2. Comprehensive Risk and Vulnerability Assessment with Strategic Recommendations for Company Growth
18.3.23. UCB S.A.
18.3.23.1. In-depth analysis of flagship products and services with direct relevance to inflammatory bowel disease treatment
18.3.23.2. Comprehensive risk and vulnerability assessment with actionable strategies for market enhancement
18.3.24. Viatris Inc.
18.3.24.1. In-depth analysis of Viatris Inc’s flagship IBD treatment products showcasing strategic alignment with market demands
18.3.24.2. Comprehensive assessment of risks and vulnerabilities facing Viatris Inc and strategic recommendations for sustainable growth
18.3.25. Zealand Pharma A/S
18.3.25.1. Comprehensive analysis of Zealand Pharma A/S flagship products and services in the inflammatory bowel disease treatment market
18.3.25.2. In-depth risk and vulnerability assessment with actionable strategic recommendations for Zealand Pharma A/S in the IBD treatment landscape
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.1.1. A Comprehensive Overview of Abbott Laboratories' Strategic Position and Market Presence in IBD Treatment
18.3.1.2. In-Depth Analysis of Abbott Laboratories' Flagship Products and Services Catering to IBD Treatment Needs
18.3.1.3. Strategic Risk and Vulnerability Assessment with Actionable Growth Enhancement Strategies for Abbott Laboratories in IBD Treatment
18.3.2. AbbVie Inc.
18.3.2.1. In-depth Analysis of AbbVie's Flagship Products and Services Delivering Solutions in IBD Therapy
18.3.2.2. Comprehensive Risk and Vulnerability Assessment with Strategic Growth Recommendations for AbbVie in IBD Treatment
18.3.3. Abivax
18.3.3.1. In-depth analysis of Abivax's flagship IBD treatment products highlighting unique clinical benefits and market differentiation
18.3.3.2. Comprehensive risk and vulnerability assessment with actionable strategies for growth and market resilience
18.3.4. Amgen Inc.
18.3.4.1. Comprehensive analysis of flagship products and services in the inflammatory bowel disease segment catering to patient and healthcare provider needs
18.3.4.2. Strategic risk assessment and vulnerability management to sustain growth and innovation in the inflammatory bowel disease treatment market
18.3.5. Bristol-Myers Squibb Company
18.3.5.1. Detailed Analysis of Bristol-Myers Squibb's Flagship Products and Their Market Relevance with Differentiators
18.3.5.2. Comprehensive Risk and Vulnerability Assessment with Strategic Recommendations for Bristol-Myers Squibb’s Future Growth in IBD Treatment Market
18.3.6. Cipla Limited
18.3.6.1. Comprehensive overview of Cipla Limited’s current role strategic positioning and core strengths in the pharmaceutical market including established presence and geographic influence
18.3.6.2. In-depth analysis of Cipla Limited’s flagship products and services for Inflammatory Bowel Disease treatment outlining key features and market alignment
18.3.6.3. Strategic risk and vulnerability assessment for Cipla Limited with actionable strategies to improve product portfolio and market positioning in evolving industry landscape
18.3.7. Eli Lilly and Company
18.3.7.1. In-depth examination of Eli Lilly’s flagship biologic therapies and their alignment with evolving patient needs in inflammatory bowel disease treatment
18.3.7.2. Comprehensive risk and vulnerability assessment with strategic recommendations for enhancing Eli Lilly’s market positioning in inflammatory bowel disease
18.3.8. Entera Bio Ltd.
18.3.8.1. Detailed analysis of Entera Bio Ltd company’s flagship products and services that define its market edge
18.3.8.2. Comprehensive risk and vulnerability assessment with actionable strategies for Entera Bio Ltd to strengthen its market position
18.3.9. FutureGen Biopharmaceutical (Beijing) Co., Ltd.
18.3.9.1. Comprehensive Analysis of Flagship Products and Services Highlighting Market Differentiators and Customer Alignment
18.3.9.2. Detailed Risk and Vulnerability Assessment With Strategic Recommendations to Strengthen Market Position and Innovation Pipeline
18.3.10. GlaxoSmithKline PLC
18.3.10.1. Detailed overview and analysis of flagship products and services focusing on inflammatory bowel disease treatment
18.3.10.2. Comprehensive risk and vulnerability assessment with actionable strategies for product and market enhancement over the next years
18.3.11. Ironwood Pharmaceuticals, Inc.
18.3.11.1. In-depth Analysis of Ironwood Pharmaceuticals’ Flagship Products and Their Market Alignment with IBD Treatment Needs
18.3.11.2. Comprehensive Risk and Vulnerability Assessment of Ironwood Pharmaceuticals with Strategic Growth Enhancement Approaches
18.3.12. Johnson & Johnson Services, Inc.
18.3.12.1. Flagship Products and Services Highlighting Their Unique Features and Market Impact
18.3.12.2. In-Depth Risk Assessment and Strategies to Strengthen Product Portfolio and Market Position Over Time
18.3.13. Merck & Co., Inc.
18.3.13.1. In-depth identification and analysis of the company’s flagship products or services that directly cater to the target market
18.3.13.2. Comprehensive assessment of risks, vulnerabilities, and strategic opportunities to enhance market position and product portfolio over the coming years
18.3.14. Morphic Therapeutic, Inc.
18.3.14.1. In-depth Analysis of Morphic Therapeutic’s Flagship Products and Their Market Alignment
18.3.14.2. Comprehensive Risk and Vulnerability Assessment with Strategic Growth Recommendations for Morphic Therapeutic
18.3.15. Nestlé S.A.
18.3.15.1. Detailed Analysis of Nestlé's Flagship Products and Services That Cater to Inflammatory Bowel Disease Treatment Market
18.3.15.2. Comprehensive Risk and Vulnerability Assessment with Strategies for Enhanced Growth in the Inflammatory Bowel Disease Treatment Market
18.3.16. OPKO Health, Inc.
18.3.16.1. In-depth Analysis of OPKO Healths Flagship Products and Services Driving Market Relevance
18.3.16.2. Comprehensive Risk and Vulnerability Assessment with Strategic Recommendations for Sustained Growth and Market Expansion
18.3.17. Pfizer Inc.
18.3.17.1. Detailed analysis of Pfizer's leading products directly addressing the inflammatory bowel disease market
18.3.17.2. Comprehensive evaluation of potential risks, vulnerabilities, and strategic growth opportunities for Pfizer in the inflammatory bowel disease treatment market
18.3.18. Sanofi SA
18.3.18.1. Detailed analysis of Sanofi's flagship products and services addressing inflammatory bowel disease treatment needs and market differentiation
18.3.18.2. Comprehensive assessment of risks and vulnerabilities with strategic recommendations for innovation and market expansion in Sanofi's inflammatory bowel disease portfolio
18.3.19. Sun Pharma Limited
18.3.19.1. Identification and In-depth Analysis of Sun Pharma's Flagship Products and Core Services Addressing IBD Treatment Needs
18.3.19.2. Comprehensive Risk and Vulnerability Assessment Identifying Strategic Growth Opportunities for Sun Pharma in IBD Treatment Market
18.3.20. Takeda Pharmaceutical Company Limited
18.3.20.1. In-depth Review of Takeda Pharmaceutical Company Limited’s Flagship Products and Services Targeting Inflammatory Bowel Disease Patients
18.3.20.2. Comprehensive Risk and Vulnerability Analysis with Strategic Recommendations for Takeda in the Inflammatory Bowel Disease Market
18.3.21. Teva Pharmaceutical Industries Ltd.
18.3.21.1. In-depth Analysis of Teva Pharmaceutical's Flagship Products Addressing Inflammatory Bowel Disease Treatment Needs
18.3.21.2. Comprehensive Risk And Vulnerability Assessment Highlighting Strategic Growth Opportunities For Teva Pharmaceutical Industries Ltd
18.3.22. TScan Therapeutics, Inc.
18.3.22.1. In-depth Analysis of TScan Therapeutics’ Flagship Products and Services Targeted at Inflammatory Bowel Disease Treatment
18.3.22.2. Comprehensive Risk and Vulnerability Assessment with Strategic Recommendations for Company Growth
18.3.23. UCB S.A.
18.3.23.1. In-depth analysis of flagship products and services with direct relevance to inflammatory bowel disease treatment
18.3.23.2. Comprehensive risk and vulnerability assessment with actionable strategies for market enhancement
18.3.24. Viatris Inc.
18.3.24.1. In-depth analysis of Viatris Inc’s flagship IBD treatment products showcasing strategic alignment with market demands
18.3.24.2. Comprehensive assessment of risks and vulnerabilities facing Viatris Inc and strategic recommendations for sustainable growth
18.3.25. Zealand Pharma A/S
18.3.25.1. Comprehensive analysis of Zealand Pharma A/S flagship products and services in the inflammatory bowel disease treatment market
18.3.25.2. In-depth risk and vulnerability assessment with actionable strategic recommendations for Zealand Pharma A/S in the IBD treatment landscape
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 2. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY MICROBIOME MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTEGRIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY OSTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RESECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STRICTUREPLASTY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RECTAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL PREPARATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CROHNS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADULT POPULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GERIATRIC POPULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC POPULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 90. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 92. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 93. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 94. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 95. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 97. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 98. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 99. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 100. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 106. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 109. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 111. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 112. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 113. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 114. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 176. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 177. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 178. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 179. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 180. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 182. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 183. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 184. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 185. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 191. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 192. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 193. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 194. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 196. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 197. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 198. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 199. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 217. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 219. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 220. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 221. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 222. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 224. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 225. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 226. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 227. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 231. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 233. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 234. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 235. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 236. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 238. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 239. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 240. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 241. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 242. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY MICROBIOME MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTEGRIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY OSTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RESECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STRICTUREPLASTY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RECTAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL PREPARATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CROHNS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADULT POPULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GERIATRIC POPULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC POPULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 90. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 92. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 93. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 94. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 95. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 97. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 98. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 99. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 100. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 106. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 109. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 111. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 112. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 113. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 114. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 176. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 177. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 178. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 179. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 180. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 182. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 183. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 184. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 185. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. GERMANY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 191. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 192. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 193. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 194. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 196. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 197. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 198. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 199. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. FRANCE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 217. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 219. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 220. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 221. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 222. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 224. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 225. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 226. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 227. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. ITALY INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 231. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 233. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 234. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 235. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 236. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 238. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 239. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 240. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 241. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 242. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. SPAIN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA
Samples
LOADING...
Companies Mentioned
The companies profiled in this Inflammatory Bowel Disease Treatment market report include:- Abbott Laboratories
- AbbVie Inc.
- Abivax
- Amgen Inc.
- Bristol-Myers Squibb Company
- Cipla Limited
- Eli Lilly and Company
- Entera Bio Ltd.
- FutureGen Biopharmaceutical (Beijing) Co., Ltd.
- GlaxoSmithKline PLC
- Ironwood Pharmaceuticals, Inc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Morphic Therapeutic, Inc.
- Nestlé S.A.
- OPKO Health, Inc.
- Pfizer Inc.
- Sanofi SA
- Sun Pharma Limited
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- TScan Therapeutics, Inc.
- UCB S.A.
- Viatris Inc.
- Zealand Pharma A/S
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 191 |
| Published | May 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 20.95 Billion |
| Forecasted Market Value ( USD | $ 26.56 Billion |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
